155 related articles for article (PubMed ID: 33747123)
1. Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker.
Jun HR; Kim H; Lee SH; Cho JH; Lee H; Yim HW; Yoon KH; Kim HS
Cardiovasc Ther; 2021; 2021():5935149. PubMed ID: 33747123
[TBL] [Abstract][Full Text] [Related]
2. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
3. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Hirai T; Yamaga R; Fujita A; Itoh T
J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
[TBL] [Abstract][Full Text] [Related]
4. Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients.
Movilli E; Camerini C; Gaggia P; Zubani R; Cancarini G
Am J Nephrol; 2018; 48(2):79-86. PubMed ID: 30071530
[TBL] [Abstract][Full Text] [Related]
5. A comparative study assessing the incidence and degree of hyperkalemia in patients on angiotensin-converting enzyme inhibitors versus angiotensin-receptor blockers.
Salik JR; Golas SB; McCoy TH
J Hum Hypertens; 2022 May; 36(5):485-487. PubMed ID: 34650213
[TBL] [Abstract][Full Text] [Related]
6. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
7. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
Maddirala S; Khan A; Vincent A; Lau K
Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
[TBL] [Abstract][Full Text] [Related]
8. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M; Tangri N
Am J Kidney Dis; 2022 Aug; 80(2):164-173.e1. PubMed ID: 35085685
[TBL] [Abstract][Full Text] [Related]
9. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity.
Tisminetzky M; Gurwitz JH; Tabada G; Reynolds K; Fortmann SP; Garcia E; Pham T; Goldberg R; Go AS
Am J Med; 2022 Dec; 135(12):1468-1477. PubMed ID: 36058306
[TBL] [Abstract][Full Text] [Related]
11. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
[TBL] [Abstract][Full Text] [Related]
12. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis.
Luo X; Xu J; Zhou S; Xue C; Chen Z; Mao Z
Clin J Am Soc Nephrol; 2023 Aug; 18(8):1019-1030. PubMed ID: 37256921
[TBL] [Abstract][Full Text] [Related]
13. Effects of angiotensin II receptor blockers on serum potassium level and hyperkalemia risk: retrospective single-centre analysis.
Fukushima S; Oishi M; Aso H; Arai K; Sasaki Y; Tochikura N; Ootsuka S; Fukuoka N; Ooba N; Kikuchi N
Eur J Hosp Pharm; 2023 Jul; 30(4):208-213. PubMed ID: 34183459
[TBL] [Abstract][Full Text] [Related]
14. Monitoring and adverse events in relation to ACE inhibitor/angiotensin receptor blocker initiation in people with diabetes in general practice: a population database study.
Mathieson L; Severn A; Guthrie B
Scott Med J; 2013 May; 58(2):69-76. PubMed ID: 23728750
[TBL] [Abstract][Full Text] [Related]
15. Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease.
Oktaviono YH; Kusumawardhani N
Acta Med Indones; 2020 Jan; 52(1):74-79. PubMed ID: 32291375
[TBL] [Abstract][Full Text] [Related]
16. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Raebel MA
Cardiovasc Ther; 2012 Jun; 30(3):e156-66. PubMed ID: 21883995
[TBL] [Abstract][Full Text] [Related]
17. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System.
Chang AR; Sang Y; Leddy J; Yahya T; Kirchner HL; Inker LA; Matsushita K; Ballew SH; Coresh J; Grams ME
Hypertension; 2016 Jun; 67(6):1181-8. PubMed ID: 27067721
[TBL] [Abstract][Full Text] [Related]
19. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
[TBL] [Abstract][Full Text] [Related]
20. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.
Bidulka P; Fu EL; Leyrat C; Kalogirou F; McAllister KSL; Kingdon EJ; Mansfield KE; Iwagami M; Smeeth L; Clase CM; Bhaskaran K; van Diepen M; Carrero JJ; Nitsch D; Tomlinson LA
BMC Med; 2020 Jul; 18(1):195. PubMed ID: 32723383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
